December 18, 2024 in Press Release

HighField Biopharmaceuticals Granted Clearance of IND in China for Clinical Trial of its Unique TRAFsomeTM T Cell Engager (HF50) To Treat Solid Tumor Cancers

HighField Biopharmaceuticals Granted Clearance of IND in China for Clinical Trial of its Unique TRAFsomeTM T Cell Engager (HF50) To Treat Solid Tumor Cancers A Phase 1 trial of HF50 to evaluate ...

Read More